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The shortage of human organ donors and the low cell quality of available liver tissues 
represent major obstacles for the clinical application of orthotropic liver transplantation 
and hepatocyte transplantation, respectively. Therefore, worldwide research groups are 
investigating  alternative  extrahepatic  cell  sources.  Recent  in  vitro  studies  have 
demonstrated  that  mesenchymal  stem  cells  (MSCs)  from  various  sources,  including 
human  bone  marrow,  adipose  tissue,  and  umbilical  cord,  can  be  differentiated  into 
hepatocyte-like cells when appropriate conditions are used. In particular, interest exists 
for  human  adipose–derived  stems  cells  (hASCs)  as  an  attractive  cell  source  for 
generating hepatocyte-like cells. The hASCs are multipotent MSCs that reside in adipose 
tissue,  with  the  ability  to  self-renew  and  differentiate  into  multiple  cell  lineages. 
Moreover,  these  cells  can  secrete  multiple  growth  factors  and  cytokines  that  exert 
beneficial effects on organ or tissue injury. In this review, we will not only present recent 
data  regarding  hASC  biology,  their  isolation,  and  differentiation  capability  towards 
hepatocytes,  but  also  the  potential  application  of  hASC-derived  hepatocytes  to  study 
drug toxicity. Additionally, this review will discuss the therapeutic potential of hASCs as 
undifferentiated cells in liver regeneration.  
KEYWORDS: human adipose–derived stem cells, liver regeneration, adipose tissue, hepatic 
differentiation, hepatocyte, hepatotoxicity, in vitro  
 
INTRODUCTION 
At present, orthotropic liver transplantation (OLT) remains the only therapeutic option for patients with 
end-stage  liver  disease,  including  (non)  alcoholic  fatty  liver  disease  and  chronic  viral  hepatitis[1]. 
However, its clinical use is limited due to the shortage of organ donors[2]. Hepatocyte transplantation has 
emerged as a promising alternative approach to OLT for the treatment of some liver-based metabolic 
disorders (e.g., Crigler Najjar) and/or acute liver failure (e.g., acute intoxication)[1]. Low cell quality, 
however, represents its main limitation[2]. Consequently, alternative extrahepatic human cell sources and, Al Battah et al.: Differentiation of hASCs into Hepatocytes  TheScientificWorldJOURNAL (2011) 11, 1568–1581 
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in particular, stem cells are being extensively investigated. Experimental evidence has indicated that adult 
stem  cells,  more  specifically  mesenchymal  stem  cells  (MSCs),  can  be  induced  into  cells  exhibiting 
hepatic  properties[3],  pointing  to  the  possibility  that  adult  stem  cell–based  therapies  might  provide 
alternative therapeutic approaches towards the treatment of liver diseases.  
MSCs are postnatal multipotent stem cells of mesodermal origin that have the capacity to differentiate 
into cells of mesenchymal lineage, including bone, fat, and cartilage[4,5]. MSCs display plasticity beyond 
their conventional mesodermal lineage. They have been induced to generate neural cells and hepatocytes 
in vitro[6,7]. In the last decade, studies by Zuk et al. indicated that human adipose tissue contains MSC 
populations,  so-called  human  adipose–derived  stem  cells  (hASCs)[8,9].  Based  on  their  biological 
properties,  including  growth  kinetics,  cell  surface  phenotype,  gene  expression,  and  differentiation 
potential,  these  cells  have  properties  that  are  similar  to  those  of  bone  marrow–derived  MSCs  (BM-
MSCs)[10,11,12].  However,  compared  to  BM-MSCs,  hASCs  have  the  relative  advantage  of 
abundance[13]. Apart from their differentiation capability, several recent reports have shown that the 
ASCs have a supportive role in organ regeneration[14,15,16,17]. In 2005, Seo et al. reported that hASCs 
cultured  in  media  supplemented  with  growth  factors  and  cytokines  yielded  a  cell  population  that 
expressed a number of hepatocyte-specific functions, such as albumin production and urea synthesis[3]. 
Several studies followed, demonstrating the ability of hASCs to differentiate into hepatocyte-like cells. 
The identification of cell populations capable of generating hepatocytes has gained immense interest. In 
this context, adipose tissue could not only represent a promising cell source for cell-based therapy of liver 
diseases, but could also be considered as a potential cell source for in vitro models used in drug safety 
testing during the preclinical phase of drug development (Fig. 1). The aim of this review is to discuss 
recent  data  regarding  hASC  biology,  including  cell  isolation,  differentiation  capability  towards 
hepatocytes, and future application of hASC-derived hepatocytes in drug toxicity studies, as well as their 
role as undifferentiated cells in supporting liver regeneration.  
INTRAHEPATIC SOURCES OF CELLS FOR LIVER REGENERATION  
The adult liver has a unique and remarkable regenerative capacity. It depends on the presence of mature, 
differentiated,  liver  parenchymal  cells  (hepatocytes)  and  liver  stem/progenitor  cells.  Hepatocytes 
constitute the first line of response to acute injury, such as partial hepatectomy, while liver progenitor 
cells function as a reservoir[18]. Hepatocytes are normally quiescent cells and, upon acute liver injury, 
display a high proliferative capacity to restore the liver mass. Indeed, transplantation studies in mice have 
shown that these cells are capable of more than 70 cell division cycles[19]. In humans and in animal 
models of chronic liver disease, intrahepatic liver stem/progenitor cell populations located within the 
canals of Hering, known as oval cells in rodents or hepatic progenitor cells (HPCs) in humans, proliferate 
whenever hepatocyte proliferation is blocked[20,21]. These bipotent, hepatic, progenitor cells are positive 
for cytokeratin 19 and α-fetoprotein, and in order to restore liver mass, can give rise to both hepatocytes 
and cholangiocytes. However, practical use of HPCs has a number of major limitations, including the 
isolation of homogeneous cell populations and large-scale expansion for application[22,23]. 
EXTRAHEPATIC SOURCES OF STEM CELLS  
Recently, attention was given to the generation of human hepatocytes from extrahepatic human stem 
cells. Stem cells are roughly classified into two major categories in accordance with their origin and their 
capacity  of  differentiation.  The  first  consists  of  pluripotent  embryonic  stem  cells  (ESCs),  which  are 
derived from embryos at the blastocyst stage. The second category is composed of adult (postnatal) stem 
cells. These are multipotent cells that are found in vivo in differentiated organs or tissues, within distinct 
regions,  the  so-called  niches,  providing  a  specialized  microenvironment  for  the  regulation  and 
maintenance of these stem cells[24,25,26]. Numerous experimental studies have clearly demonstrated that  Al Battah et al.: Differentiation of hASCs into Hepatocytes  TheScientificWorldJOURNAL (2011) 11, 1568–1581 
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FIGURE 1. ASCs are self-renewing, making them a scale-up cell source. They can also differentiate 
along the hepatic lineage when cultured in serum-free medium supplemented with hepatic-specific 
induction  factors.  ASC-derived  hepatocyte-like  cells  might  provide  the  possibility  to  be  used  in 
toxicity prediction assays. In addition, undifferentiated ASCs secrete growth factors and cytokines that 
are involved in liver regeneration. Abbreviations: Dex: dexamethasone; FGF: fibroblast growth factor; 
HGF:  hepatocyte  growth  factor;  IL-6:  interleukin  6;  NGF:  neural  growth  factor;  ITS:  insulin-
transferrin-sodium selenite; VEGF: vascular endothelial growth factor  
extrahepatic stem cells, including embryonic and adult (nonhepatic) stem cells, are able to differentiate 
towards the hepatic lineage[27]. In addition, the recent approach of reprogramming human differentiated 
cells into pluripotent cells, known as induced pluripotent stem cells (iPSCs), has opened a new era to 
obtain iPSC-derived hepatic cells[28,29,30,31,32].  
ADULT STEM CELLS FROM ADIPOSE TISSUE  
Nomenclature  
Different nomenclatures have been suggested to describe ASCs, e.g., adipose stem/stromal cells (ASCs), 
processed lipoaspirate cells, adipose-derived stromal cells, human multipotent adipose-derived stem cells, 
adipose mesenchymal stem cells, and preadipocytes. In order to avoid confusion, the International Fat Al Battah et al.: Differentiation of hASCs into Hepatocytes  TheScientificWorldJOURNAL (2011) 11, 1568–1581 
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Applied  Technology  Society  adopted  the  term  adipose-derived  stem  cells  (ASCs)  to  describe  the 
multipotent, plastic-adherent, cell type isolated from adipose tissue[33,34] . 
Isolation, Culture, and Proliferation of hASCs 
Adult human adipose tissue originates from the embryonic mesoderm and represents, for regenerative 
medicine, an abundant and less invasive source of MSCs than bone marrow[8,35]. hASCs can be easily 
isolated from routine liposuction (lipoaspirate) and reconstructive surgery (lipectomy) waste materials. In 
brief,  the  lipoaspirate  or  minced  fat  tissue  is  extensively  washed  with  phosphate  buffered  saline 
containing 5% penicillin/streptomycin. The adipose tissue is digested with collagenase to break down the 
stroma,  then  filtered  and  centrifuged.  After  centrifugation,  the  resulting  pellet  is  termed  the  stromal 
vascular fraction (SVF). Under proper conditions, cells within the SVF subsequently adhere to plastic 
tissue culture dishes and exhibit a fibroblast-like appearance (Fig. 2A)[8,36]. The SVF is a heterogeneous 
population of stromal cells, including ASCs, fibroblasts, endothelial cells, pericytes, smooth muscle cells, 
and circulating cell types, such as immune cells and hematopoietic stem cells. The adherent multipotent 
ASCs are capable of differentiating to several cell lineages[8,9,37,38,39,40,41,42,43]. 
 
FIGURE  2.  Morphology  of  undifferentiated  hASCs  (A)  and  when  cultured  in  hepatic  induction  medium  (B). 
Undifferentiated  hASCs  display  a  fibroblast-like  shape,  while  during  hepatic  differentiation,  they  acquire  a 
polygonal or round shape. Phase contrast magnification 100.  
In principle, the selection of hASCs out of SVF is based on their physical adherence to plastic tissue 
culture dishes. Due to the lack of specific cell surface markers, a number of strategies have been employed 
to define this ASC population, including the use of immunomagnetic beads coated with specific antibodies, 
such  as  CD34,  CD105,  and  CD271[44,45],  fluorescence  activated  cell  sorting[46],  and  the  SP  (side 
population) approach based on aldehyde dehydrogenase activity[47,48].   
hASCs are cultured and expanded
 in media, such as minimal essential media (MEM), Dulbecco’s 
modified
 Eagle’s medium (DMEM), Roswell Park Memorial Institute-1640 medium (RPMI-1640), and 
Dulbecco’s
  modified  Eagle’s  medium/Ham’s  nutrient  mixture  F-12
  (DMEM/F12)  supplemented  with 
10% fetal bovine
 serum (FBS)[49]. Serum supplementation is pivotal because it provides the cells with 
vital nutrients, attachment factors, and growth factors[50]. Today, efforts are being made to work under 
serum-free conditions, in particular, the use of serum-replacement factors, e.g., human platelet lysate, has 
become a promising technique[51].  Al Battah et al.: Differentiation of hASCs into Hepatocytes  TheScientificWorldJOURNAL (2011) 11, 1568–1581 
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The proliferation assay showed that ASCs obtained from 20 donors, and cultured under standard 
conditions  (10%  FBS),  exhibited  an  average  population  doubling  time  of  60  h[8].  Generally,  ASCs 
display a cell doubling time within 2–4 days[11,47]. Additionally, ASCs can be cultured extensively (up 
to  30  passages),  but  as  any  normal  somatic  cell,  they  have  a  finite  life  span  in  vitro  and  undergo 
replicative senescence upon prolonged culture[11,52,53].    
Characterization of hASCs 
Characteristics  of  hASCs  include  positive  staining  for  osteopontin,  osteonectin,  Muc18  (cluster  of 
differentiation [CD] 146); receptors for extracellular matrix (ECM) proteins, i.e., interstitial cell adhesion 
molecules  (ICAM-1,  CD54),  ALCAM  (CD166),  tetraspan  (CD9),  integrin  β1  (CD29),  integrin  α4 
(CD49d),  endoglin  (SH2,  CD105),  Thy1  (CD90),  CD13,  CD73,  CD44;  and  negative  staining  for 
hematopoietic markers, such as CD45, and CD34, and endothelial markers, such as CD31[33,54,55].  
hASCs  also  exhibit  immunomodulatory  properties  because  they  lack  expression  of  the  major 
histocompatibility  complex  class  II.  ASCs  inhibit  activation  and  proliferation  of  immune  cells  in 
vitro[56]. Their impact on immune cells is due to both cell-to-cell contact and the release of soluble 
factors,  such  as  hepatocyte  growth  factor  (HGF),  leukemia  inhibitory  factor,  and  prostaglandin 
E2[56,57,58]. Although the mechanisms of ASC-induced immunosuppression are unclear, this property 
could be valuable for the potential use of ASCs in immunosuppressive and regenerative medicine[56]. 
PROTOCOLS, MARKERS, AND FUNCTIONAL ANALYSIS OF HEPATOCYTE-LIKE 
CELLS FROM HASCS 
The  majority  of  studies  on  stem  cell–derived  hepatocytes  are  based  on  the  use  of  ESCs,  liver 
stem/progenitor cells, and bone marrow–derived cells[27]. However, emerging evidence has shown that 
hASCs  represent  an  interesting  alternative  cell  source[3,43,59,60,61,62].  Multilineage  plasticity  of 
hASCs is well established, but with respect to endodermal differentiation, particularly towards the hepatic 
lineage, only a limited number of reports have been published with a number of highly promising results. 
The methodology used is summarized in Table 1.  
Seo et al.[3] demonstrated for the first time that hASCs can differentiate into hepatocyte-like cells by 
a one-step protocol using HGF, oncostatin M (OSM), and dimethyl sulfoxide (DMSO). The differentiated 
cells  show  functional  characteristics  of  parenchymal  liver  cells,  including  uptake  of  low-density 
lipoprotein (LDL) and urea production. In addition, they found that differentiated hASCs can in vivo 
repopulate the livers of severe combined immunodeficient (SCID) mice suffering from acute liver injury 
induced by carbon tetrachloride (CCl4) injections.  
Another  interesting  work  is  the  one  reported  by  Talens-Visconti  et  al.[59]  that  comparatively 
demonstrated that adult human MSCs, derived from bone marrow and adipose tissue, exhibit similar 
expression  patterns  of  surface  protein  markers  and  a  comparable  hepatic  differentiation  potential. 
Evidence was also provided that differentiated hASCs express drug metabolizing enzymes at the mRNA 
level, e.g., cytochrome P450 2E1 (CYP2E1) and CYP3A4. 
Banas et al.[60] further investigated the hepatic differentiation of the CD105
+ hASCs. Over a period 
of  3  weeks,  they  observed  morphological  changes during  hepatic induction. Specifically,  the  hASCs 
changed  from  flat,  elongated,  spindle-shaped  cells  to  rounded  epithelial  cells  with  tight  cell-to-cell 
interactions, and bile canaliculi structures became visible. Hepatic maturation was followed for another 2 
weeks, during which the number of cells exhibiting the hepatic phenotype increased substantially as 
demonstrated by LDL uptake. More importantly, transplantation of CD105
+ ASC-derived hepatocyte-like 
cells into mice showed their incorporation into the liver parenchyma. An additional report from that group 
showed that hASCs can be differentiated in vitro towards hepatocyte-like cells by a short induction and 
that the latter can improve liver functions when transplanted in vivo[61]. Al Battah et al.: Differentiation of hASCs into Hepatocytes  TheScientificWorldJOURNAL (2011) 11, 1568–1581 
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TABLE 1 
Overview of ASCs Isolation, Expansion, and Hepatic Differentiation  
Isolation Procedure  Expansion Medium  Hepatic Differentiation Medium  Ref. 
Collagenase type I 
followed by one-step 
centrifugation  
60% DMEM-LG/5% FBS, 40% 
MCDB-201, 1x ITS, 10
-9 M Dex, 
10
-4 M ascorbic acid 2-phosphate, 
10 ng/ml EGF, 100 U penicillin, 
1000 U streptomycin 
DMSO (0.1%), HGF (10 ng/ml), OSM (10 
ng/ml)  
[3] 
Collagenase type I 
followed by serial 
centrifugations 
DMEM-LG, 15% human serum, 50 
μg/ml gentamicine 
EGF (20 ng/ml), bFGF (10 ng/ml), HGF 
(20 ng/ml), nicotinamide (4.9 mmol/l), 
OSM (20 ng/ml), Dex (1 μmol/l), ITS 
(10 μl/ml), BSA (1.25 mg/ml), linoleic 
acid (190 μmol/l) 
[59] 
Collagenase type I 
followed by positive 
selection of CD105
+ 
DMEM, 10% FBS  Transferrin (5 µg/ml), hydrocortisone-21-
hemisuccinate (10
-6 M), BSA (0.5 
mg/ml), ascorbic acid (2 mM), EGF (20 
ng/ml), insulin (5 µg/ml), Dex (10
-8 M), 
HGF (150 ng/ml), FGF1 (300 ng/ml), 
FGF4 (25 ng/ml), OSM (30 ng/ml), Dex 
(2  10
-5 mol/l) 
[60] 
Collagenase type I 
followed by positive 
selection of CD105
+ 
DMEM, 10% FBS  Activin A (20 ng/ml), FGF4 (20 ng/ml), 
transferrin (5 µg/ml), hydrocortisone-
21-hemisuccinate (10
-6 mol/l), BSA (0.5 
mg/ml), ascorbic acid (2 mmol/l), EGF 
(20 ng/ml), insulin (5 µg/ml), Dex (10
-8 
M), HGF (150 ng/ml), FGF1 (100 
ng/ml), FGF4 (25 ng/ml), OSM (30 
ng/ml), Dex (2  10
-5 mol/l), 1x ITS, 
nicotinamide (0.05 mmol/l), DMSO 
(0.1%) 
[61] 
Collagenase followed 
by Percoll density 
gradient 
centrifugation 
60% DMEM, 40% MCDB, 5 mg/ml 
apotransferrin, 5 ng/ml selenous 
acid, 5 mg/ml linoleic acid, 5 
mg/ml bovine insulin, 100 mM 
ascorbic acid 2-phosphate, 1 nM 
Dex, 10 ng/ml PDGF, 10 ng/ml 
EGF, 100 U/ml penicillin, 10 
mg/ml streptomycin, 15% FCS 
5′Azacytidine (20 µM), human 
hepatocyte maintenance medium, FCS 
(2%), HGF (40 ng/ml), EGF (20 ng/ml) 
[43] 
Collagenase type II 
followed by 
Lymphoprep density 
gradient 
centrifugation  
60% DMEM-LG, 40% MCDB-201, 
1x ITS, 1 nM Dex, 100 mM 
ascorbic acid 2-phosphate, 10 
ng/mL EGF, 5% FBS 
Dex (1 nM), ascorbic acid (100 μM), EGF 
(10 ng/ml), bFGF (10 ng/ml), HGF (10 
ng/ml), OSM (10 ng/ml), DMSO (0.1%)  
[62] 
Abbreviations:  bFGF:  basic  fibroblast  growth  factor;  BSA:  bovine  serum  albumin,  Dex:  dexamethasone;  DMSO: 
dimethyl sulfoxide; EGF: epidermal growth factor; FBS: fetal bovine serum; FCS: fetal calf serum; FGF1: fibroblast 
growth factor 1; ITS: insulin-transferrin-sodium selenite; LG: low glucose; OSM: oncostatin M; PDGF: platelet-derived 
growth factor.  
Aurich et al.[43] used induction media supplemented with HGF and epidermal growth factor (EGF) 
to obtain hepatocyte-like cells from hASCs. Prior to hepatic induction, they treated the hASCs with the 
epigenetically modifying substance 5′azacytidine for 24 h. After 21 days of induction, they found that 
differentiated cells could store glycogen, synthesize urea, and metabolize 7-ethoxyresorufin to resorufin, 
indicative  of  CYP1A  enzyme  activity.  hASCs  were  transplanted  into  the  liver  of  immunodeficient 
Pfp/Rag2-/- mice with and without prior in vitro hepatic differentiation. The results demonstrated that Al Battah et al.: Differentiation of hASCs into Hepatocytes  TheScientificWorldJOURNAL (2011) 11, 1568–1581 
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differentiated  cells  expressed  albumin  and  hepatocyte  paraffin  1.  Moreover,  predifferentiated  hASCs 
showed better cell engraftment in comparison to those that were undifferentiated. After 10 weeks, more 
than 10% of all hepatocytes in the host liver were replaced by hepatocyte-like cells derived from hASCs.  
By  using  a  floating  culture  technique,  hepatocyte-like  cell  clusters  could  be  obtained  from 
hASCs[62]. After culture in medium supplemented with hepatic induction factors, hepatocyte-like cell 
clusters  were  generated,  exhibiting  functional  properties  of  hepatocytes  as  characterized  by  gene 
expression analysis and functional assays. Transplantation of these cell clusters into nonobese diabetic-
SCID mouse with chronic liver injury resulted in a significant improvement of serum albumin and total 
bilirubin levels[62].  
Our  group  recently  investigated  the  hepatic  potential  of  BM-MSCs  by  administrating  hepatic 
inductive  factors  in  a  sequential  way,  reflecting  the  embryonic  liver  development  in  vivo[63].  This 
approach resulted in the efficient production of human hepatocyte-like cells (approximately 25%) that 
displayed  hepatic  functions,  including  albumin  secretion,  urea  production,  and  CYP1A1  activity.  To 
demonstrate the feasibility of this approach on other MSC types, we applied the same sequential protocol 
on  hASCs  and  this  resulted  in  hepatocyte-like  cells  that  expressed  hepatic-associated  markers  as 
characterized by immunocytochemistry at the protein level (unpublished data).  
MOLECULAR MECHANISMS UNDERLYING THE PLASTICITY OF HASCS 
TOWARDS A HEPATOCYTE-LIKE PHENOTYPE 
At  present,  the  molecular  mechanisms  underlying  the  plasticity  of  hASCs  towards  a  hepatocyte-like 
phenotype remain poorly understood. Yamamoto and colleagues examined the gene expression profiles of 
hASC-derived hepatocytes in order to identify the genes responsible for hepatic differentiation using 
several microarray methods. The resulting sets of differentially expressed genes were comprehensively 
analyzed in order to identify the pathways expressed in hASC-derived hepatocytes. Microarray analysis 
revealed that the gene expression pattern of hASC-derived hepatocytes was similar to that of adult human 
hepatocytes and liver. Further analysis showed that enriched categories of genes and signaling pathways, 
such as complementary activation and the blood clotting cascade in the hASC-derived hepatocytes, were 
relevant  to  liver-specific  functions.  Notably,  decreases  in  Twist  and  Snail  expression  indicated  that 
mesenchymal-to-epithelial  transition  (MET)  occurred  during  differentiation  of  hASCs  into 
hepatocytes[64].  
More recently, Saulnier et al.[65] compared the expression profile of the hASCs before and after in 
vitro hepatogenic treatment by means of a high-throughput molecular analysis. They identified several 
targets that depict the numerous biological functions exerted by the liver, including protein metabolism, 
innate immune response regulation, and biodegradation of toxic compounds. Furthermore, microarray 
analysis highlighted down-regulation of transcripts associated with the mesenchymal lineage, such as N-
cadherin-2 and vimentin, while epithelial-related genes were overexpressed, such as the vascular cell 
adhesion  molecule.  Altogether,  these  reports  suggest  that  cellular  plasticity  observed  in  hASCs  is 
dependent on MET.   
THERAPEUTIC POTENTIALITY OF HASCS IN ANIMAL MODELS OF LIVER 
DISEASES  
Besides their high differentiation potential, several recent studies have shown that MSCs, in particular 
BM-MSCs, have the ability to support the proliferation and functionality of hepatocytes either via direct 
cell-cell  contact  or  production  of  bioactive  factors,  such  as  cytokines[66].  This  ability  has  been 
investigated as well in vitro as in vivo. Both cocultivation of hepatocytes with BM-MSCs or adding 
conditioned medium of BM-MSCs to hepatocytes demonstrated that MSCs were able to sustain albumin 
and ammonia production at higher levels than was the case in control cells. Interleukin (IL)-6 was one of Al Battah et al.: Differentiation of hASCs into Hepatocytes  TheScientificWorldJOURNAL (2011) 11, 1568–1581 
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the  factors  involved[67].  Furthermore,  when  BM-MSCs  were  administrated  to  a  D-galactosamine–
induced fulminant hepatic failure rat model, using either conditioned medium or cell lysates, the mortality 
among these animals was significantly reduced[68].  
However, in vitro exposure of hepatocytes to hASCs has not yet been investigated. To date, studies 
on  animal  models  reported  the  beneficial  effects  of  hASCs  in  promoting  liver  regeneration. 
Transplantation of hASCs into SCID mice with acute liver failure caused by CCl4 injection revealed that 
undifferentiated  hASCs  were  able  to  engraft  into  the  liver  and  improve  its  function.  Investigators 
postulated that the beneficial effects of hASCs could be due to MSC ability to secrete bioactive molecules 
that  modulate  the  local  microenvironment,  and  contribute  to  hepatocyte  proliferation  and  function. 
Interestingly, it was found that undifferentiated hASCs in vitro produce a large number and volume of 
bioactive factors, such as HGF, vascular endothelial growth factors, nerve growth factor, and IL-6[15].  
Although these findings have potential, the approach of using hASCs or MSCs in general is in its 
infancy and plenty of issues still remain to be addressed before application is justified in clinical settings. 
ASCs are a heterogeneous cell population and this represents a main limit to their use. A standardized 
protocol  for  isolating  a  specific  cell  population  is  lacking.  This  heterogeneity  in  isolation  methods 
generates variable results that make the interpretation of data very difficult[69]. The behavior of ASCs 
within the liver could also be questioned, as in vivo studies demonstrated that transplanted MSCs may 
contribute  to  scar-forming  myofibroblasts  in  the  liver  and  thus  enhance  the  fibrotic  process[70]. 
Moreover, risk of tumor formation after transplantation it is not yet well studied. It has been shown that 
hASCs  undergo  malignant  transformation  when  prolonged  passaging  over  4  months  takes  place[71]. 
Despite many unresolved issues in this field, at present, one clinical trial using autologous hASCs for 
liver regeneration has been registered (http://clinicaltrials.gov). 
POTENTIAL APPLICATION OF hASC-DERIVED HEPATOCYTE-LIKE CELLS IN 
TOXICOPHARMACOLOGICAL SCREENING ASSAYS 
Besides  the  presence  of  other  cell  types,  the  adult  human  liver  is  predominantly  composed  of 
parenchymal cells, so-called hepatocytes. They comprise approximately 80% of the total liver mass[72]. 
Hepatocytes perform various, essential liver functions. They are polarized epithelial cells. Through the 
apical surface, they secrete bile and detoxification products by transport proteins into bile canaliculi. 
Through  the  basolateral  surfaces,  they  take  up  substances  from  the  blood  and  secrete  serum  factors 
back[73]. Moreover, their unique structure, along with various enzymes expressed in hepatocytes, show 
that they are involved in protein synthesis, transformation of carbohydrates, synthesis of cholesterol, bile 
salts,  and  phospholipids.  Also,  detoxification  and  toxification  (activation)  of  exogenous  substances 
mainly  occurs  in  hepatocytes[74].  These  features  make  hepatocytes  an  attractive  tool,  not  only  for 
studying xenobiotic biotransformation, but also as target cells for toxic reactions[75,76]. Indeed, while the 
ultimate effect of biotransformation is to facilitate removal of the xenobiotic from the body, it can also 
result  in  formation  of  reactive  metabolites,  which  directly  or  indirectly  may  cause  hepatic 
injury[77,78,79,80]. This impairment of cellular function can culminate in cell death by apoptosis or 
necrosis, and in hepatotoxicity or so-called drug-induced liver injury (DILI)[77,78,81]. Animal models 
and  in  vitro  studies  with  respect  to  DILI  reveal  different  mechanisms  that  might  be  relevant  to  the 
development of liver damage. In human hepatocytes, DILI can be initiated through organelle dysfunction. 
Mitochondrial dysfunction is a good example, including disruption of mitochondrial energy production 
and/or release of proapoptotic proteins into the cytoplasm that end up in hepatocyte necrosis or apoptosis 
and cytolytic hepatitis[82]. Additionally, other potential mechanisms may be involved: parent drugs and 
their reactive metabolites might also specifically inhibit other hepatocellular functions, such as the apical 
bile  salt  export  pump  (ABCB11)[77].  In  this  case,  the  subsequent  intercellular  accumulation  of  its 
substrates (e.g., conjugated bile salts) may result in the development of cholestatic liver cell injury, also 
known as cholestasis[77,83].  Al Battah et al.: Differentiation of hASCs into Hepatocytes  TheScientificWorldJOURNAL (2011) 11, 1568–1581 
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As described above, DILI can have detrimental effects on hepatocytes and may lead to liver failure. 
Therefore, DILI has emerged as a major challenge for the pharmaceutical industry. It is a leading cause of 
postmarketing drug failure, as well as at the preclinical and clinical phases of drug development[77,82]. 
Thus,  identification  of  potential  liver  toxicity  in  the  preclinical  phase  could  be  a  critical  step  for 
pharmaceutical companies in order to reduce drug attrition and to bring drugs on the market with fewer 
side effects. Liver-based in vitro models could represent key experimental systems here, in particular 
when they are human derived.  
During the development of pharmaceuticals, the potential toxicity of the lead molecules is carefully 
assessed. Usually, experimental animals are used. This approach has, besides ethical considerations, a 
number of limitations, including the fact that they are time consuming, expensive, and animals frequently 
do not fully reflect the human response[84]. For these reasons, the development of in vitro cell models, 
preferably  human  based,  is  receiving  growing  interest,  particularly  in  the  preclinical  phase  of  drug 
development. 
Several  in  vitro  human  hepatic  models  have  been  developed  in  the  past  few  decades,  including 
perfused liver, liver slices, primary liver cells, liver cell lines, transgenic cell lines, subcellular fractions, 
and  isolated  enzyme  systems[85,86].  In  particular,  cultured  primary  hepatocytes,  either  derived from 
rodents[87] or humans, have been shown to be useful in toxicity studies, as they maintain a number of in 
vivo  liver  functions[78,84,85,88].  During  the  last  years,  however,  the  availability  of  human  primary 
hepatocytes became more limited by the scarcity of donor organs because of transplantation possibilities. 
Furthermore, once brought in culture, they dedifferentiate and lose their phenotypic functionality[78,89]. 
Therefore, a significant demand exists to obtain fully functional  human hepatocytes from alternative 
sources. In that respect, stem cells could represent a potential source to provide an unlimited number of 
human hepatocytes, as they retain proliferation capacity in vitro and, under appropriate conditions, may 
differentiate into a variety of functional cell types, including hepatocytes[27,31,90,91].     
Both pluripotent stem cells (ESCs and iPSCs) and somatic stem cells show good potential and ability 
to  acquire  liver  metabolic  functions  with  respect  to  drug  metabolism  after  in  vitro  hepatogenic 
differentiation[92,93,94,95,96]. The use in toxicology of hepatocyte-like cells derived from whatever the 
source of human stem cells implies that they should be metabolically competent and express phase I and 
phase II xenobiotic metabolizing enzymes, as well as transporter proteins at levels consistent with those 
measured in the liver or at least in primary hepatocyte cultures[97]. Given the importance of CYP activity 
for drug  inactivation,  prodrug  activation,  or the  generation  of  toxic  metabolites,  assessment of these 
enzymes in hASC-derived hepatocyte-like cells is critical and, as yet, incomplete. Whereas some studies 
of hASC-derived hepatocyte-like cells have detected CYP transcripts or proteins such as CYP1A1, 1B1, 
2E1, 2C9, 3A4, 3A7 and 7A, actual enzyme concentrations have not been quantified[43,59,60,62]. In two 
reports, CYP activity comparable to that of adult human hepatocytes has been described. Aurich et al. 
detected  CYP1A  expression  as  measured  by  ethoxyresorufin-O-deethylase  activity  in  hepatocyte-like 
cells[43], whereas Okura et al. reported CYP3A4 activity as detected by hydroxylation of 7-benzyloxy-4-
trifluoromethyo-coumarin[62].  The  data  obtained  from  these  studies  suggest  that  hASC-derived 
hepatocytes exhibit a level of functionality, but as indicated above, in order to determine the feasibility of 
using the hASC-derived hepatic cells in studies of drug-induced hepatotoxicity, these differentiated cells 
really need to develop a complete biotransformation system, not only by expressing phase I enzymes, but 
also phase II enzymes and phase III transporters in order to be considered metabolically competent.   
CONCLUSION 
Accessibility, abundance, and immunosuppressive properties of hASCs have attracted attention for the 
use of these cells in regenerative medicine, in particular for liver diseases. Subsequently, obtaining mature 
hepatocytes from adipose-derived stem cells has become a priority research area. As mentioned in this 
review, in vitro studies have shown that, under proper stimulation, hASCs are capable of differentiating 
into endodermal cells. They can acquire hepatic characteristics including polygonal morphology (Fig. Al Battah et al.: Differentiation of hASCs into Hepatocytes  TheScientificWorldJOURNAL (2011) 11, 1568–1581 
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2B),  albumin  secretion,  and  expression  of  several  CYP  enzymes.  Moreover,  transplantation  of 
undifferentiated hASCs seems to ameliorate liver injury and to improve liver functions. These properties 
suggest that transplantation of hASCs as fully or partly differentiated cells could have a positive effect on 
liver  regeneration.  Before  clinical  applications  can  be  considered,  more  research  work  is  needed  to 
understand and elucidate the main mechanisms whereby hASCs improve liver functions in vivo. 
While some efforts were undertaken to prove the presence and functionality of phase I enzymes in 
hASC-derived hepatocyte-like cells, the expression and, in particular, activity of phase II and phase III 
transporter proteins should also be addressed. This is necessary to evaluate to what extent hASC-derived 
hepatocyte-like cells can be used as a human in vitro cell model to predict hepatotoxicity in the early 
phases of drug development. 
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